Lack of Evidence for Vaccine-Associated Enhanced Disease From COVID-19 Vaccines Among Adults in the Vaccine Safety Datalink
-
8-2024
-
-
Source: Pharmacoepidemiol Drug Saf. 33(8):e5863
Details:
-
Alternative Title:Pharmacoepidemiol Drug Saf
-
Personal Author:
-
Description:Purpose:
Vaccine-associated enhanced disease (VAED) is a theoretical concern with new vaccines, although trials of authorized vaccines against SARS-CoV-2 have not identified markers for VAED. The purpose of this study was to detect any signals for VAED among adults vaccinated against coronavirus disease 2019 (COVID-19).
Methods:
In this cross-sectional study, we assessed COVID-19 severity as a proxy for VAED among 400 adults hospitalized for COVID-19 from March through October 2021 at eight US healthcare systems. Primary outcomes were admission to an intensive care unit (ICU) and severe illness (score ≥6 on the World Health Organization [WHO] Clinical Progression Scale). We compared the risk of outcomes among those who had completed a COVID-19 vaccine primary series versus those who were unvaccinated. We incorporated inverse propensity weights for vaccination status in a doubly robust regression model to estimate the causal average treatment effect.
Results:
The causal risk ratio in vaccinated versus unvaccinated was 0.36 (95% confidence interval [CI], 0.15–0.94) for ICU admission and 0.46 (95% CI, 0.25–0.76) for severe illness.
Conclusion:
Among hospitalized patients, reduced disease severity in those vaccinated against COVID-19 supports the absence of VAED.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:39155049
-
Pubmed Central ID:PMC11377022
-
Document Type:
-
Funding:
-
Volume:33
-
Issue:8
-
Collection(s):
-
Main Document Checksum:
-
File Type:
-
Supporting Files:No Additional Files
